Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.
With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.
This 14th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.
In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 14th AIBCC will award the 8th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.
We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.
Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.
The official language of the Meeting is English. No simultaneous translation will be provided.
Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will request the MCE Accreditation.
The credit certification is subject to:
We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.
The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.
Participants can send one or more abstracts.
The form should be filled out by following specific guidelines:
Abstracts will be selected by the Scientific Committee and will be shown during the poster session on September 22nd from 8 am. Poster size: 70 (wide) x 100 (high).
People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European participants).
Abstracts should be sent within July 1st. A confirmation will be sent by email within July 20th.
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
University of Padua (I)
The University of Texas - MD Anderson Cancer Center
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
German Breast Group
Department of Medicine and Research
University of Frankfurt (D)
Medical Oncology Service
Hospital Universitario Gregorio Marañon
Europa Donna Italia
Department of Medical Oncology
European Institute of Oncology (IEO)
President of ESTRO; President-Elect of ECCO
Department of Radiation Oncology
Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi
Population screening vs risk-adapted surveillance
9.50 Pharmacological prevention: how and whom?
A look into the future: multigene panels
Evolution in surgical management of the axilla
Do margins still matter for in situ and invasive lesions?
Radiation therapy: what is the real target to aim at
Multidisciplinary Tumor Board 1 – Locoregional treatment
Diet: myths and facts
Cardiovascular and metabolic
HER2 testing guidelines: new ASCO/CAP 2018
Molecular stratification of HER2+ and TNBC
Lobular breast cancer: a separate entity?
Insights in resistance to CDK4/6 inhibitors
Targeting the immune system: hopes and hypes
Combining radiotherapy and immunotherapy
New promising agents
Extended adjuvant endocrine therapy: why? for whom? with what?
Risk adapted adjuvant treatment for HER2+
Most promising ongoing trials in early disease
Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (early breast cancer)
Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2018 and best poster award
Lecture of the Awardee
New therapeutic algorithms
Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer
Adjourn and final evaluation questionnaire
The slides of the 2017 meeting are now available.